Fibrocell Science Inc (FCSC) - Financial and Strategic SWOT Analysis Review

September 2020 | 42 pages | ID: F413624DD75EN
GlobalData

Abstracts

Fibrocell Science Inc (FCSC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Fibrocell Science Inc (Fibrocell Science) is an autologous cell and gene therapy company which discovers and develops therapies for diseases affecting the skin and connective tissue. The company’s product pipeline comprises FCX-007, a lead candidate for the treatment of recessive dystrophic epidermolysis bullosa; FCX-013 for linear scleroderma; and a research program for the treatment of arthritis and related conditions. Fibrocell Science utilizes its proprietary autologous fibroblast technology to develop personalized biologics for skin diseases. It has a manufacturing facility in Exton, Pennsylvania; and operates along with its subsidiaries in the US and Switzerland. Fibrocell Science is headquartered in Exton, Pennsylvania, the US.

Fibrocell Science Inc Key Recent Developments

Aug 14,2019: Fibrocell reports second quarter 2019 financial results and recent operational highlights
May 15,2019: Fibrocell reports first quarter 2019 financial results and recent operational highlights
Mar 27,2019: Fibrocell: Financial results for the twelve months ended December 31, 2018

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Fibrocell Science Inc - Key Facts
Fibrocell Science Inc - Key Employees
Fibrocell Science Inc - Key Employee Biographies
Fibrocell Science Inc - Major Products and Services
Fibrocell Science Inc - History
Fibrocell Science Inc - Company Statement
Fibrocell Science Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Fibrocell Science Inc - Business Description
Fibrocell Science Inc - Corporate Strategy
Fibrocell Science Inc - SWOT Analysis
SWOT Analysis - Overview
Fibrocell Science Inc - Strengths
Fibrocell Science Inc - Weaknesses
Fibrocell Science Inc - Opportunities
Fibrocell Science Inc - Threats
Fibrocell Science Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Fibrocell Science Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 14, 2019: Fibrocell reports second quarter 2019 financial results and recent operational highlights
May 15, 2019: Fibrocell reports first quarter 2019 financial results and recent operational highlights
Mar 27, 2019: Fibrocell: Financial results for the twelve months ended December 31, 2018

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Fibrocell Science Inc, Key Facts
Fibrocell Science Inc, Key Employees
Fibrocell Science Inc, Key Employee Biographies
Fibrocell Science Inc, Major Products and Services
Fibrocell Science Inc, History
Fibrocell Science Inc, Subsidiaries
Fibrocell Science Inc, Joint Venture
Fibrocell Science Inc, Key Competitors
Fibrocell Science Inc, Ratios based on current share price
Fibrocell Science Inc, Annual Ratios
Fibrocell Science Inc, Annual Ratios (Cont...1)
Fibrocell Science Inc, Interim Ratios
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Fibrocell Science Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Fibrocell Science Inc, Performance Chart (2014 - 2018)
Fibrocell Science Inc, Ratio Charts
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Caladrius Biosciences Inc
Abeona Therapeutics Inc
Plus Therapeutics Inc
Miragen Therapeutics Inc
Krystal Biotech Inc